Blogs

Categories

Select a sub-category to view results

Icon
Films and Coatings
vail 4ml
Pharmaceutical Packaging Components
Icon
Prefillable Systems
Icon
Self Injection Devices
Icon
Vial Containment Solutions
Icon
Washing and Sterilization
Icon
Reconstitution and Transfer Devices

Select a sub-category to view results

Icon
Analytical Lab Services
Icon
Contract Manufacturing
Icon
Fill-Finish
Icon
Regulatory Support

Select a sub-category to view results

Icon
Cell and Gene Therapy Packaging
Icon
Drug Development Process
Icon
Regulatory Challenges
Icon
Transitioning to Combination Products

Select a sub-category to view results

Icon
Corporate Development
Icon
ESG/Sustainability
Icon
One West Team (Employee Culture)
Icon
Our Culture of Giving (Philanthropy)
Icon
Research and Development

Previous Blogs

AccelTRA Stoppers

By Prabhaharan Sankaran

June 02, 2021

For any drug, selection of the appropriate primary packaging components is essential to having a containment system that ensures quality, safety, and stability. The primary packaging components are selected based on various factors, which include chemical compatibility with the drug product ingredients and dimensional fit with mating packaging components. Optimized fit among mating packaging components is essential for flawless fill-finish processing.

Vial Containment Systems

By Page McAndrew

December 20, 2019

Recently, there has been discussion in the industry regarding the utility of polymer-based vial containment systems for the storage and transport of gene therapy drug products, which can be performed as low as -80oC. Since it is known that all polymers are gas permeable, discussion has centered on whether polymer-based systems can sufficiently restrict ingress of oxygen (during refrigerated storage) and carbon dioxide (during transport on dry ice).

Blue West logo with Diamond

By Whitney Winters

June 13, 2013

When converting a drug product from its initial container closure system to a prefillable syringe system or device, component elastomer formulations and sterilization mode equivalency can help ease the transition, minimize regulatory filing times and mitigate risk for pharmaceutical manufacturers.